Innovative Eyewear Inc 8-K

What Happened

• Innovative Eyewear, Inc. (LUCY) entered an inducement letter agreement with a holder of existing warrants and closed an offering on July 9, 2026. The holder agreed to exercise 2,200,544 existing warrants for cash at a reduced exercise price of $1.35 (originally $2.60). In exchange, the company issued new unregistered Series J warrants to purchase up to 6,601,632 shares; the Series J Warrants were sold at $0.125 each, have a $1.10 exercise price, are exercisable immediately, and expire 24 months after the resale registration statement is effective.

Key Details

• Gross proceeds to the company from the exercise of existing warrants and issuance of the new warrants: approximately $3.0 million (before placement agent fees and offering expenses). Net proceeds intended for working capital and general corporate purposes.
• Registration obligations: Innovative Eyewear will file a resale registration statement for the New Warrant Shares within 15 days and use commercially reasonable efforts to have it declared effective within 45 calendar days (75 days if the SEC conducts a full review); the company must keep it effective until no New Warrants or New Warrant Shares remain outstanding.
• Placement agent: H.C. Wainwright & Co., LLC acted as exclusive placement agent (engagement dated July 7, 2026). Fees: 7.5% cash fee of gross proceeds + 1.0% management fee, $50,000 accountable expenses, $25,000 non-accountable expenses, and $15,950 clearing expenses. Wainwright received warrants (PA Warrants) to purchase up to 165,041 shares (exercise price $1.6875, exercisable immediately, 24-month term after registration effectiveness).
• Issuance restrictions: Company agreed not to issue or announce new equity or file certain registration statements for 30 days after closing, and not to effect Variable Rate Transactions for one year after closing (subject to specified exceptions).

Why It Matters

• This transaction provided immediate cash (~$3.0M gross) to Innovative Eyewear while creating potential future dilution through the sizable issuance of Series J warrants (up to 6.6M shares) and placement-agent warrants (~165k shares). Investors should note the reduced exercise price on the exercised existing warrants ($1.35) and the mechanics that require registration for resale of the new warrants’ underlying shares. Placement agent fees and warrants increase the effective cost and dilution of the financing.